Literature DB >> 22263712

Buprenorphine-naloxone maintenance following release from jail.

Joshua D Lee1, Ellie Grossman, Andrea Truncali, John Rotrosen, Andrew Rosenblum, Stephen Magura, Marc N Gourevitch.   

Abstract

Primary care is understudied as a reentry drug and alcohol treatment setting. This study compared treatment retention and opioid misuse among opioid-dependent adults seeking buprenorphine/naloxone maintenance in an urban primary care clinic following release from jail versus community referrals. Postrelease patients were either (a) induced to buprenorphine in-jail as part of a clinical trial, or (b) seeking buprenorphine induction post release. From 2007 to 2008, N = 142 patients were new to primary care buprenorphine: n = 32 postrelease; n = 110 induced after community referral and without recent incarceration. Jail-released patients were more likely African American or Hispanic and uninsured. Treatment retention rates for postrelease (37%) versus community (30%) referrals were similar at 48 weeks. Rates of opioid positive urines and self-reported opioid misuse were also similar between groups. Postrelease patients in primary care buprenorphine treatment had equal treatment retention and rates of opioid abstinence versus community-referred patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22263712      PMCID: PMC3310898          DOI: 10.1080/08897077.2011.620475

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  15 in total

1.  Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99.

Authors:  Sheila M Bird; Sharon J Hutchinson
Journal:  Addiction       Date:  2003-02       Impact factor: 6.526

2.  [High-dose buprenorphine substitution during incarceration.]

Authors:  Catherine Reynaud-Maurupt; Yves Caer; Noëlle Escaffre; Murielle Gagneau; Anne Galinier; Jean-Noël Marzo; Fadi Meroueh
Journal:  Presse Med       Date:  2005-04       Impact factor: 1.228

3.  The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates.

Authors:  V Tomasino; A J Swanson; J Nolan; H I Shuman
Journal:  Mt Sinai J Med       Date:  2001-01

4.  Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Authors:  Ira L Mintzer; Mark Eisenberg; Maria Terra; Casey MacVane; David U Himmelstein; Steffie Woolhandler
Journal:  Ann Fam Med       Date:  2007 Mar-Apr       Impact factor: 5.166

5.  A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system.

Authors:  Kate A Dolan; James Shearer; Margaret MacDonald; Richard P Mattick; Wayne Hall; Alex D Wodak
Journal:  Drug Alcohol Depend       Date:  2003-10-24       Impact factor: 4.492

Review 6.  Consensus statement on office-based treatment of opioid dependence using buprenorphine.

Authors:  David A Fiellin; Herbert Kleber; Jeanne G Trumble-Hejduk; A Thomas McLellan; Thomas R Kosten
Journal:  J Subst Abuse Treat       Date:  2004-09

Review 7.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

8.  Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.

Authors:  Stephen Magura; Joshua D Lee; Jason Hershberger; Herman Joseph; Lisa Marsch; Carol Shropshire; Andrew Rosenblum
Journal:  Drug Alcohol Depend       Date:  2008-10-18       Impact factor: 4.492

9.  Buprenorphine treatment in an urban community health center: what to expect.

Authors:  Chinazo Cunningham; Angela Giovanniello; Galit Sacajiu; Susan Whitley; Pamela Mund; Robert Beil; Nancy Sohler
Journal:  Fam Med       Date:  2008 Jul-Aug       Impact factor: 1.756

10.  Treating homeless opioid dependent patients with buprenorphine in an office-based setting.

Authors:  Daniel P Alford; Colleen T LaBelle; Jessica M Richardson; James J O'Connell; Carole A Hohl; Debbie M Cheng; Jeffrey H Samet
Journal:  J Gen Intern Med       Date:  2007-02       Impact factor: 5.128

View more
  21 in total

1.  Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.

Authors:  Soteri Polydorou; Stephen Ross; Peter Coleman; Laura Duncan; Nichole Roxas; Anil Thomas; Sonia Mendoza; Helena Hansen
Journal:  Psychiatr Serv       Date:  2016-10-17       Impact factor: 3.084

2.  Psychiatric comorbidity, red flag behaviors, and associated outcomes among office-based buprenorphine patients following Hurricane Sandy.

Authors:  Arthur R Williams; Babak Tofighi; John Rotrosen; Joshua D Lee; Ellie Grossman
Journal:  J Urban Health       Date:  2014-04       Impact factor: 3.671

3.  Initiation of buprenorphine during incarceration and retention in treatment upon release.

Authors:  Nickolas Zaller; Michelle McKenzie; Peter D Friedmann; Traci C Green; Samuel McGowan; Josiah D Rich
Journal:  J Subst Abuse Treat       Date:  2013-03-27

4.  Trends and mental health correlates of nonmedical opioid use among criminal justice-involved African American men.

Authors:  Joi-Sheree' Knighton; Danelle Stevens-Watkins; Michele Staton; Kevin Pangburn
Journal:  Addict Behav       Date:  2018-04-30       Impact factor: 3.913

5.  Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.

Authors:  Helena Hansen; Carole Siegel; Joseph Wanderling; Danae DiRocco
Journal:  Drug Alcohol Depend       Date:  2016-05-04       Impact factor: 4.492

6.  Pre-Incarceration Rates of Nonmedical Use of Prescription Drugs among Black Men from Urban Counties.

Authors:  Paris Wheeler; Danelle Stevens-Watkins; Joi-Sheree' Knighton; Carlos Mahaffey; Dominiqueca Lewis
Journal:  J Urban Health       Date:  2018-08       Impact factor: 3.671

7.  A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Terrence T Fitzgerald; Kevin E O'Grady; Frank J Vocci
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

8.  At the Expense of a Life: Race, Class, and the Meaning of Buprenorphine in Pharmaceuticalized "Care".

Authors:  Alexandrea E Hatcher; Sonia Mendoza; Helena Hansen
Journal:  Subst Use Misuse       Date:  2017-11-21       Impact factor: 2.164

9.  Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness.

Authors:  Allison G Robertson; Michele M Easter; Hsiu-Ju Lin; Linda K Frisman; Jeffrey W Swanson; Marvin S Swartz
Journal:  J Subst Abuse Treat       Date:  2017-12-12

10.  Buprenorphine Treatment for Probationers and Parolees.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kathryn A Couvillion; Laura J Sudec; Kevin E O'Grady; Frank J Vocci; Hamin Shabazz
Journal:  Subst Abus       Date:  2014-04-04       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.